Halneuron®️
The non-opioid painkiller ​

Presentations

the American Academy of Pain Management 26th Annual Clinical Meeting, September 17-20, 2015 at the Gaylord National Hotel, Washington, DC.

A Translational Research Study. IASP 16th World Congress on Pain. Sep 26-30, 2016, Yokohama, Japan.

Scientific Publications

J. Marcil, J.-S. Walczak, J. Gruindon, et al. Antinociceptive effects of tetrodotoxin (TTX) in rodents.

British Journal of Anaesthesia. May 4, 2006

Christian Rosker, Birgit Lohberger, Doris Hofer, et al. The TTX metabolite 4,9-anhydro-TTX in a highly specific blocker of the Nav1.6 voltage-dependent sodium channel.

Am J Physilo cell Physiol 293: C000-C000, 2007. First published May 23, 2007

Hagen NA, Fisher KM, Lapointe B, duSouich P, Chary S, Moulin D, et al. An open-label, multi-dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer-related pain.

J Pain Symptom Manage. 2007 Aug 34 (2) 171-182

Antonio Guzman, Antonio R.Fernandez de Henestrosa, Ana-Paz Marin, Anh Ho, et al. Evaluation of the Genotoxic potencial of the natural neurotoxin Tetrodotoxin (TTX) in a battery of in vitro and in vivo Genotoxicity assays.

Mutation Research 634 (2007) 14-24

Neil A.Hagen, Patrick du Souich, Bernard Lapointe, May Ong-Lam, Benoit Dubuc, David Walde, Robin Love, Anh Ho Ngoc. Tetrodotoxin for Moderate to severe Cancer Pain: A Randomized Double Blind, Parallel Design Multicenter Study.

J Pain Symptom Manage. 2008 Apr; 35 (4) 420-429

Neil A.Hagen, Bernard Lapointe, May Ong-Lam, Benoit Dubuc, David Walde, B.Gagnon, R. Love, R Goel, P Hawley, Anh Ho Ngoc. Patrick du Souich. Amulticentre open-label safety and efficacy study of tetrodotoxin for cancer pain. 

Current oncology, Volume 18, Number 3, page e109-e116, 2011

Charles B. berde, Umeshkumar Athiraman, Barak Yahalom,et al. Tetrodocotixin-Bupivacaine-Epinephrine Combinations for prolonged local anesthesia. 

Marine Drugs, 2011, 9, 2717-2728

Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial. 

Pain Research and Management. Volume 2017, Article ID 7212713, 2017-5-7

Hagen NA, Fisher KM, Lapointe B, du Souich P, Chary S, Moulin D, et al. An open-label, multi-dose efficacy and safety study if intramuscular tetrodotoxin in patients with severe cancer-related pain.

J Pain Symptom Manage 2007; 34:171-182.

Hagen NA, du Souich P, Lapointe B, Ong-Lam M, Dubuc B, Walde D. Tetrodotoxin for moderate to severe cancer pain:

A randomized, double-blind, parallel design multicenter study. J Pain Symptom Manage 2008; 35:420-429.

Salas MM, McIntyre MK, Petz LN, Korz W, Wong D, Clifford JL. Tetrodotoxin suppresses thermal hyperalgesia and mechanical allodynia in a rat full thickness thermal injury pain model.

Neurosci Lett. 2015; 607:108-113.

Hagen NA, Cantin L, Constant J, Haller T, Blaise G, Ong-Lam M, du Souich P, Korz W, Lapointe B. Tetrodotoxin for Moderate to Severe Cancer-Related Pain: 

A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial. Pain Res Manag. 2017; 2017:7212713.